|
Research and development is long, expensive, and risky.
With so much invested, failure is not an option.
3D has a proven preparation process for communicating and negotiating with FDA AND EMEA regulators at every stage of product development.
3D ACT™ (Analysis, Content Development, Testing) has demonstrated success with drugs, devices, and challenging regulatory issues.
From key regulatory discussions to FDA advisory committee meetings, 3D’s team of experts works side-by-side with your researchers, investigators, doctors, advocacy groups, and executives to anticipate regulatory scrutiny, influence regulators, and build to "yes".
• 3D ACT™ Process for FDA Advisory Committee Meetings and CHMP Oral Hearings

We Wrote The Book!
To order a copy, click here
• 3D ACT™ Process for Key Regulatory Discussions (SPA, SAPA, EOP2)
|